Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Radiation Oncology
Would you offer adjuvant radiotherapy to a young patient with microinvasive lobular carcinoma (< 1 mm) in a background of LCIS?
If a patient is <50 years old, would this change your recommendation?
Answer from: Radiation Oncologist at Community Practice
I would favor RT as part of BCS but would also like to know the LCIS type (pleomorphic or not) to better quantify the risk of IBTR.
Sign in or Register to read more
18942
Related Questions
Is there any contraindication for a patient receiving omalizumab for treatment of her lung aspergillosis to receive adjuvant breast radiotherapy?
Is 5fx APBI and no endocrine therapy a new standard of care for women over 70 years old with low-risk breast cancer given the interim analysis of the EUROPA trial?
Are you comfortable combining palliative radiotherapy with capivasertib/fulvestrant?
What are the advantages/disadvantages of using static IMRT vs VMAT when treating breast cancer?
What is your preferred method of surveillance after mastectomy?
In the post-mastectomy setting, are there situations where only the regional nodes or targeted nodal basis are covered?
Would you omit post-lumpectomy radiotherapy for high clinical risk, but low molecular risk DCIS?
If a patient has multiple PET-avid level 3, supraclavicular, or IMN nodes that are small and would have been considered negative by size criteria with traditional imaging, that are no longer positive on PET after chemotherapy, would you try to boost these nodes?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
Would you consider radiation omission for a patient with a Stage I breast cancer with an elevated Oncotype Dx?